Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iltamiocel - Cook MyoSite

Next Previous
X
Search
Drug Profile

Iltamiocel - Cook MyoSite

Alternative Names: AMDC - Cook MyoSite; AMDC-USR; Autologous muscle derived cells - Cook MyoSite; Autologous muscle derived stem cell therapy - Cook MyoSite; Autologous muscle derived stem cells - Cook MyoSite; CMI-AMDC

Latest Information Update: 06 Sep 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cook MyoSite
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Faecal incontinence; Stress incontinence
  • Phase II Bladder dysfunction
  • Discontinued Ischaemic heart disorders

Most Recent Events

  • 27 Aug 2024 Cook MyoSite withdraws a phase III JPN1 trial in Stress incontinence in Japan (Parenteral) (NCT03997318)
  • 01 Dec 2023 Phase-III clinical trials in Faecal Incontinence (Treatment-experienced) in USA (Parenteral) (NCT05776277)
  • 20 Mar 2023 Cook MyoSite plans a phase III DigniFI trial for Faecal Incontinence (Treatment-experienced) (Parenteral, Injection) (NCT05776277)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top